The U.S. is seeing a "quad-demic" as cases of COVID-19, flu, RSV and norovirus spread at the same time. Experts said this is ...

Moderna's been anything but a high-flying growth stock in this investor's portfolio. So is it high time he gave up on this one? The post Moderna’s meant to be a red-hot growth stock. What on earth’s ...

The company's newer product, an RSV ( respiratory syncytial virus) vaccine, has also underperformed, contributing "minimal ...

Moderna (NASDAQ: MRNA) was one of the hottest companies of early pandemic times, delivering a coronavirus vaccine to market ...

Moderna ( MRNA) cut its 2025 forecast by $1 billion Monday, citing weak demand for its newest vaccine as well as slow sales ...

Dr Zachary Rubin took to TikTok to explain the testing process doctors use for human metapneumovirus (HMPV), amid a spike in ...

CEO Stéphane Bancel emphasised saving cash as integral in the company’s bid to parlay Covid-19 profits into future profitability.

RSV cases peaked earlier this month, but experts ask people to remain vigilant in preventing its spread. RSV is a respiratory ...

Moderna is down 80% from its 52-week high as revenues continue to fall and the new RSV vaccine has performed poorly. Read my ...

Care for the flu is generally supportive — meaning rest, hydration, and over-the-counter medication, but as the Mayo Clinic ...

Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) ...

A number of cases of Influenza A and RSV have been reported across the state, including right here in Central Texas. Making ...